| pubmed-article:6254339 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6254339 | lifeskim:mentions | umls-concept:C0006675 | lld:lifeskim |
| pubmed-article:6254339 | lifeskim:mentions | umls-concept:C0229671 | lld:lifeskim |
| pubmed-article:6254339 | lifeskim:mentions | umls-concept:C0238462 | lld:lifeskim |
| pubmed-article:6254339 | lifeskim:mentions | umls-concept:C0006668 | lld:lifeskim |
| pubmed-article:6254339 | lifeskim:mentions | umls-concept:C0030859 | lld:lifeskim |
| pubmed-article:6254339 | lifeskim:mentions | umls-concept:C1948023 | lld:lifeskim |
| pubmed-article:6254339 | lifeskim:mentions | umls-concept:C0475610 | lld:lifeskim |
| pubmed-article:6254339 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:6254339 | pubmed:dateCreated | 1981-1-29 | lld:pubmed |
| pubmed-article:6254339 | pubmed:abstractText | The efficiency of pentagastrin, calcium and whisky in raising serum immunoreactive calcitonin (S-iCT) concentrations was analysed in 6 patients with medullary carcinoma of the thyroid and in 8 healthy controls. All 6 patients responded to pentagastrin with a significant increase in S-iCT, 5 responded to calcium and only 3 to whisky. In the 8 controls no or only a modest increase in S-iCT occurred following pentagastrin, calcium and whisky with no difference between the three. It is concluded that pentagastrin is the most useful stimulative agent for ICT secretion in patients with C-cell neoplasms. In selected cases the additional use of calcium could be advantageous. | lld:pubmed |
| pubmed-article:6254339 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6254339 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6254339 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:6254339 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6254339 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6254339 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6254339 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6254339 | pubmed:issn | 0349-652X | lld:pubmed |
| pubmed-article:6254339 | pubmed:author | pubmed-author:HansenH HHH | lld:pubmed |
| pubmed-article:6254339 | pubmed:author | pubmed-author:NielsenH EHE | lld:pubmed |
| pubmed-article:6254339 | pubmed:author | pubmed-author:MosekildeLL | lld:pubmed |
| pubmed-article:6254339 | pubmed:author | pubmed-author:EmmertsenK... | lld:pubmed |
| pubmed-article:6254339 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6254339 | pubmed:volume | 19 | lld:pubmed |
| pubmed-article:6254339 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6254339 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6254339 | pubmed:pagination | 85-9 | lld:pubmed |
| pubmed-article:6254339 | pubmed:dateRevised | 2006-12-5 | lld:pubmed |
| pubmed-article:6254339 | pubmed:meshHeading | pubmed-meshheading:6254339-... | lld:pubmed |
| pubmed-article:6254339 | pubmed:meshHeading | pubmed-meshheading:6254339-... | lld:pubmed |
| pubmed-article:6254339 | pubmed:meshHeading | pubmed-meshheading:6254339-... | lld:pubmed |
| pubmed-article:6254339 | pubmed:meshHeading | pubmed-meshheading:6254339-... | lld:pubmed |
| pubmed-article:6254339 | pubmed:meshHeading | pubmed-meshheading:6254339-... | lld:pubmed |
| pubmed-article:6254339 | pubmed:meshHeading | pubmed-meshheading:6254339-... | lld:pubmed |
| pubmed-article:6254339 | pubmed:meshHeading | pubmed-meshheading:6254339-... | lld:pubmed |
| pubmed-article:6254339 | pubmed:meshHeading | pubmed-meshheading:6254339-... | lld:pubmed |
| pubmed-article:6254339 | pubmed:meshHeading | pubmed-meshheading:6254339-... | lld:pubmed |
| pubmed-article:6254339 | pubmed:meshHeading | pubmed-meshheading:6254339-... | lld:pubmed |
| pubmed-article:6254339 | pubmed:meshHeading | pubmed-meshheading:6254339-... | lld:pubmed |
| pubmed-article:6254339 | pubmed:meshHeading | pubmed-meshheading:6254339-... | lld:pubmed |
| pubmed-article:6254339 | pubmed:meshHeading | pubmed-meshheading:6254339-... | lld:pubmed |
| pubmed-article:6254339 | pubmed:meshHeading | pubmed-meshheading:6254339-... | lld:pubmed |
| pubmed-article:6254339 | pubmed:meshHeading | pubmed-meshheading:6254339-... | lld:pubmed |
| pubmed-article:6254339 | pubmed:year | 1980 | lld:pubmed |
| pubmed-article:6254339 | pubmed:articleTitle | Pentagastrin, calcium and whisky stimulated serum calcitonin in medullary carcinoma of the thyroid. | lld:pubmed |
| pubmed-article:6254339 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6254339 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:6254339 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6254339 | lld:pubmed |
